1.
The use of benzalkonium chloride in topical glaucoma treatment.
Hedengran Anne
Acta OphthalmolDec 20231 citationsReview
5 articles in GJC
3.
Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement.
Thein Anna-Sophie, Hedengran Anne, Azuara-Blanco Augusto, Arita Reiko, Cvenkel Barbara, Gazzard Gus et al.
Am J OphthalmolMay 20228 citationsReview
Experts defined key outcomes (e.g., ocular surface, dryness, quality of life) for consistently assessing glaucoma eye drop side effects in clinical trials, improving future research comparability and patient safety.
4.
Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties.
Hedengran Anne, Freiberg Josefine Clement, Hansen Pernille May, Jacobsen Jette, Larsen Susan Weng, Harloff-Helleberg Stine et al.
Acta OphthalmolMay 202212 citationsBasic Science
Generic BAK-preserved travoprost caused more goblet cell loss than branded PQ-preserved travoprost, suggesting PQ preservation is preferable for glaucoma treatment and generics aren't identical.
5.
Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis.
Hedengran Anne, Steensberg Alvilda T, Virgili Gianni, Azuara-Blanco Augusto, Kolko Miriam
Br J OphthalmolFeb 202028 citationsSystematic Review
This review found no significant difference in IOP reduction or common adverse events between BAK-preserved and preservative-free/alternatively preserved glaucoma drops, but safety data had high uncertainty.
All 5 articles loaded